Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
BMY Bristol Myers Squibb	$46.72 -1.4%	$47.47	$41.90 ▼ $63.33	$96.38B	0.36	12.75 million shs	9.93 million shs
MRK Merck & Co., Inc.	$79.35 -0.8%	$79.37	$73.31 ▼ $128.73	$200.78B	0.39	13.50 million shs	11.58 million shs
PFE Pfizer	$24.27 -0.8%	$24.07	$20.92 ▼ $31.54	$139.12B	0.58	41.93 million shs	33.44 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
BMY Bristol Myers Squibb	-1.44%	-1.36%	-0.32%	-6.23%	+9.56%
MRK Merck & Co., Inc.	-0.78%	-5.22%	+0.13%	+0.48%	-36.91%
PFE Pfizer	-0.80%	-4.30%	+1.24%	+7.65%	-19.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGN Allergan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	4.8502 of 5 stars	3.2	3.0	4.2	4.0	2.6	3.3	1.3
MRK Merck & Co., Inc.	4.9946 of 5 stars	3.2	4.0	5.0	4.2	3.5	2.5	3.8
PFE Pfizer	4.9724 of 5 stars	3.2	3.0	4.2	4.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGN Allergan	0.00	N/A	N/A	N/A
BMY Bristol Myers Squibb	2.32	Hold	$57.69	23.49% Upside
MRK Merck & Co., Inc.	2.43	Hold	$108.69	36.98% Upside
PFE Pfizer	2.45	Hold	$28.55	17.66% Upside

Current Analyst Ratings Breakdown

Latest AGN, MRK, PFE, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
7/10/2025	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$99.00 ➝ $98.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
4/30/2025	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform	$22.00 ➝ $23.00
4/30/2025	PFE Pfizer	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral	$29.00 ➝ $27.00
4/30/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$26.00 ➝ $27.00
4/30/2025	PFE Pfizer	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform	$28.00 ➝ $26.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGN Allergan	$16.09B	3.95	$36.70 per share	5.26	$177.28 per share	1.09
BMY Bristol Myers Squibb	$48.30B	1.97	$5.81 per share	8.04	$8.08 per share	5.78
MRK Merck & Co., Inc.	$64.17B	3.10	$9.39 per share	8.45	$18.33 per share	4.33
PFE Pfizer	$63.63B	2.17	$4.33 per share	5.61	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGN Allergan	-$5.27B	$17.64	N/A	10.65	1.63	-15.44%	8.46%	5.31%	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.50	7.67	2.48	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.55	8.01	0.83	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	7.62	8.01	0.89	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest AGN, MRK, PFE, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGN Allergan	$2.96	1.53%	N/A	16.78%	N/A
BMY Bristol Myers Squibb	$2.48	5.31%	N/A	92.88%	17 Years
MRK Merck & Co., Inc.	$3.24	4.08%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.09%	N/A	124.64%	16 Years

Latest AGN, MRK, PFE, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGN Allergan	0.31	1.01	0.84
BMY Bristol Myers Squibb	2.65	1.28	1.17
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGN Allergan	83.91%
BMY Bristol Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AGN Allergan	0.08%
BMY Bristol Myers Squibb	0.07%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGN Allergan	17,400	329.00 million	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

AGN, MRK, PFE, and BMY Headlines

Recent News About These Companies

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?

July 21 at 9:15 PM | finance.yahoo.com

Pfizer (NYSE:PFE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

July 21 at 11:12 AM | marketbeat.com

Van Strum & Towne Inc. Purchases 15,900 Shares of Pfizer Inc. (NYSE:PFE)

July 21 at 10:04 AM | marketbeat.com

HighPoint Advisor Group LLC Has $5.46 Million Stake in Pfizer Inc. (NYSE:PFE)

July 21 at 9:55 AM | marketbeat.com

Edgemoor Investment Advisors Inc. Acquires 194,853 Shares of Pfizer Inc. (NYSE:PFE)

July 21 at 9:12 AM | marketbeat.com

Teachers Retirement System of The State of Kentucky Purchases 18,135 Shares of Pfizer Inc. (NYSE:PFE)

July 21 at 7:27 AM | marketbeat.com

J.W. Cole Advisors Inc. Acquires 97,092 Shares of Pfizer Inc. (NYSE:PFE)

July 21 at 7:06 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by IFP Advisors Inc

July 21 at 6:39 AM | marketbeat.com

Sen. Ron Wyden Sells Off Shares of Pfizer Inc. (NYSE:PFE)

July 21 at 5:19 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Los Angeles Capital Management LLC

July 20 at 9:47 AM | marketbeat.com

Optimist Retirement Group LLC Purchases 55,823 Shares of Pfizer Inc. (NYSE:PFE)

July 20 at 8:59 AM | marketbeat.com

OneAscent Financial Services LLC Purchases 41,481 Shares of Pfizer Inc. (NYSE:PFE)

July 20 at 7:34 AM | marketbeat.com

Elyxium Wealth LLC Has $640,000 Holdings in Pfizer Inc. (NYSE:PFE)

July 20 at 7:20 AM | marketbeat.com

5 High-Yield Stock Picks to Add to Your Dividend Portfolio

July 20 at 6:50 AM | fool.com

Calton & Associates Inc. Boosts Position in Pfizer Inc. (NYSE:PFE)

July 20 at 6:38 AM | marketbeat.com

Csenge Advisory Group Has $2.14 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 20 at 6:17 AM | marketbeat.com

Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns

July 20 at 3:54 AM | finance.yahoo.com

Morningstar Investment Services LLC Has $1.34 Million Holdings in Pfizer Inc. (NYSE:PFE)

July 19 at 9:27 AM | marketbeat.com

Foundry Partners LLC Has $18.97 Million Stock Position in Pfizer Inc. (NYSE:PFE)

July 19 at 8:50 AM | marketbeat.com

Private Advisor Group LLC Purchases 42,238 Shares of Pfizer Inc. (NYSE:PFE)

July 19 at 8:09 AM | marketbeat.com

After recall, Pfizer warns of 'near-term stock out' of penicillin product used to treat syphilis in pregnant women

July 19 at 7:50 AM | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
The Top Insider Sells From Q2: Buy, Sell, or Hold?
By Thomas Hughes | June 30, 2025
View The Top Insider Sells From Q2: Buy, Sell, or Hold?
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

AGN, MRK, PFE, and BMY Company Descriptions

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Bristol Myers Squibb NYSE:BMY

$46.72 -0.64 (-1.36%)

Closing price 07/21/2025 03:58 PM Eastern

Extended Trading

$46.80 +0.08 (+0.18%)

As of 07/21/2025 07:55 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$79.35 -0.61 (-0.77%)

Closing price 07/21/2025 03:58 PM Eastern

Extended Trading

$79.38 +0.03 (+0.04%)

As of 07/21/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.26 -0.21 (-0.84%)

Closing price 07/21/2025 03:58 PM Eastern

Extended Trading

$24.36 +0.09 (+0.37%)

As of 07/21/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time